Pre-Clinical Research
Filter News
Found 6,128 articles
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
Sosei Confirms New Data Demonstrating AZD4635, a Novel A2A Receptor Antagonist, Induces Anti-Tumor Immunity Alone and in Combination With Anti-PD-L1 in Preclinical Models
4/18/2018
New data presented at 2018 AACR Meeting
-
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
4/18/2018
INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pronounced long term immunity
-
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
-
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
-
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
-
Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions
4/17/2018
Data show ability of destabilizing domain technology platform to regulate expression of secreted and membrane-bound proteins in cell therapies
-
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
4/17/2018
Lm platform targets common mutations in tumor driver genes.
-
Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals' EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer
4/16/2018
Studies Conducted by MD Anderson Cancer Center Elucidate the Mechanisms by Which EP-100 Kills Ovarian Cancer Cells on Its Own and Synergistically in Combination with a Leading PARP Inhibitor
-
Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH
4/12/2018
Late-Breaking Poster Presented at The International Liver Congress
-
Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting
4/12/2018
Gritstone Oncology announced that preclinical data highlighting the company’s tumor-specific neoantigen (TSNA) identification platform, EDGETM (Epitope Discovery in cancer GEnomes), and a novel, potent TSNA delivery approach will be presented during two poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting.
-
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
4/11/2018
First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
-
GT Biopharma, Inc. Announces it has Completed Enrollment in Proof-of-concept Clinical Trial for its Novel Treatment for Motion Sickness
4/10/2018
The primary objective of the study will be to demonstrate the anti-motion sickness efficacy of transdermal GTP-011.
-
Constellation Pharmaceuticals closed on a financing round worth $100 million. The company plans to use the funds to advance several clinical trials.
-
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
-
SignalRx to Present on its First-In-Class Triple CDK4-6/PI3K/BRD4 Inhibitor SRX3177 for Treating Cancer at the 13th Annual Drug Discovery Chemistry 2018 Meeting
4/5/2018
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the presentation of its novel triple CDK4-6/PI3K/BRD4 inhibitor program and first-in-class triple inhibitor SRX3177.
-
Specialised Therapeutics Asia Initiates Early Access Program For Neratinib
4/5/2018
Specialised Therapeutics Asia today announces the initiation of an early access program for neratinib, an extended adjuvant treatment for early-stage HER2-positive (HER2+) breast cancer.
-
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
-
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
-
Shares of Arsanis, Inc. are inching up this afternoon following the company’s announcement of a licensing deal with Austria-based BB100, LLC, a subsidiary of Bravos Biosciences.